Show simple item record

Authordc.contributor.authorEyzaguirre C., Francisca 
Authordc.contributor.authorCodner Dujovne, Ethel 
Cita de ítemdc.identifier.citationRevista Medica de Chile, Volumen 134, Issue 2, 2018, Pages 239-250
Abstractdc.description.abstractInsulin analogues, developed by molecular engineering, have structural changes in the A and B insulin chains. These modifications change their action profile, rendering insulin replacement closer to physiology. Rapid acting analogues like lispro, a spart and glulisine, are absorbed rapidly from the subcutaneous tissue to the circulation. In addition, two long acting insulin analogues have been developed: glargine and detemir. The combination of a long acting insulin, to maintain baseline levels, and multiple daily doses of a rapid acting analogue are the mainstay of basal-bolus therapy. Multiples studies have compared human insulin (NPH and regular) with insulin analogues in patients with type 1 or 2 diabetes mellitus, showing an improvement in the metabolic control, fewer hypoglycemic events and better quality of life. In summary, insulin analogues offer new therapeutic options and allow an individualized intensive treatment.
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
Link to Licensedc.rights.uri
Sourcedc.sourceRevista Medica de Chile
Keywordsdc.subjectDiabetes mellitus, insulin dependent
Keywordsdc.subjectInsulin, long acting
Keywordsdc.subjectPro insulin
Títulodc.titleInsulin analogues: Searching for a physiological replacement Análoges de insulina: En búsqueda del reemplazo fisiológico
Document typedc.typeArtículo de revista
Indexationuchile.indexArtículo de publicación SCOPUS

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile